Meeting
2015 Gastrointestinal Cancers Symposium
A phase III clinical trial of intra-arterial yttrium-90 glass microspheres in the treatment of patients with unresectable hepatocellular carcinoma.
Authors
Maria Angela Karpf
BTG International Inc., West Conshohocken, PA
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01556490
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 477)
DOI
10.1200/jco.2015.33.3_suppl.477
Abstract #
477
Poster Bd #
E44
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Comparison of liver-directed combined radiotherapy versus sorafenib in patients with locally advanced hepatocellular carcinoma with portal vein tumor thrombosis: An Asian Liver Radiotherapy Group Study.
First Author: Jinsil Seong
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Impact of baseline liver function on survival outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with camrelizumab + rivoceranib vs sorafenib: A post hoc analysis of study CARES-310.
First Author: Arndt Vogel
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world survival outcomes and treatment patterns in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Results from the OREIOS study.
First Author: Stephen Chan
Poster
2023 ASCO Annual Meeting
Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).
First Author: George Lau